Suchergebnisse
Suchergebnisse:
16. Nov. 2018 · Adrenomed AG. @adrenomed. An innovative biomarker-guided #precisionmedicine solution for patients in acute care with #sepsis and #septicshock. #enibarcimab. Hennigsdorf, Deutschland adrenomed.com Joined November 2018. 218 Following.
AdrenoMed AG is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: developing precision medicine to rescue vascular integrity and saving the lives of critically ill patients with limited treatment options. The Company’s lead product candidate is Enibarcimab (INN, former name: Adrecizumab), a clinical-stage ...
13. Okt. 2022 · In #November, meet our CEO and CFO at: @LSXLeaders’ Inv€$tival #Showcase November 14, 2022, in-person in #London, UK. 13 Oct 2022 07:41:09
Für weitere Informationen besuchen Sie bitte www.adrenomed.com und folgen Sie Adrenomed direkt auf LinkedIn und Twitter . AdreCIZUMAB (INN: Enibarcimab) Antikörper-basierte Therapie zur Verbesserung der Gefäßintegrität
13. Okt. 2022 · Hennigsdorf/Berlin (Germany), April 10, 2024 –AdrenoMed AG, the vascular integrity company, today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate enibarcimab, a first-in-class non-neutralizing. 10.
An innovative biomarker-guided precision medicine solution for patients in acute care with sepsis and septic shock | Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical...
21. Feb. 2020 · Hennigsdorf/Berlin (Germany), February 21, 2020 – Adrenomed AG, the vascular integrity company, today reported positive top-line results from its proof-of-concept AdrenOSS-2 Phase II trial. AdrenOSS-2 evaluated the safety, tolerability and efficacy of Adrecizumab, a first-in-class monoclonal antibody targeting the vasoprotective ...
